BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lopez-Beltran A, Cimadamore A, Montironi R, Cheng L. Molecular pathology of urothelial carcinoma. Hum Pathol 2021;113:67-83. [PMID: 33887300 DOI: 10.1016/j.humpath.2021.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Mohanty SK, Lobo A, Cheng L. The 2022 revision of World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol 2022:S0046-8177(22)00224-6. [PMID: 36084769 DOI: 10.1016/j.humpath.2022.08.006] [Reference Citation Analysis]
2 Rüschoff JH, Moch H. Molekularpathologische Diagnostik des Harnblasenkarzinoms – prädiktive und prognostische Marker. Onkologie 2022;28:742-752. [DOI: 10.1007/s00761-022-01219-3] [Reference Citation Analysis]
3 Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D. Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 2022. [DOI: 10.1016/j.urolonc.2022.07.002] [Reference Citation Analysis]
4 Cheng L, Zhang S, Wang M, Lopez-Beltran A. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Hum Pathol 2022:S0046-8177(22)00150-2. [PMID: 35700749 DOI: 10.1016/j.humpath.2022.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Duan L, Liu X, Luo Z, Zhang C, Wu C, Mu W, Zuo Z, Pei X, Shao T. G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer. Genes 2022;13:693. [DOI: 10.3390/genes13040693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Valderrama BP, González-Del-Alba A, Morales-Barrera R, Peláez Fernández I, Vázquez S, Caballero Díaz C, Domènech M, Fernández Calvo O, Gómez de Liaño Lista A, Arranz Arija JÁ. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021). Clin Transl Oncol 2022;24:613-24. [PMID: 35347572 DOI: 10.1007/s12094-022-02815-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol 2022:S0923-7534(22)00110-7. [PMID: 35176457 DOI: 10.1016/j.annonc.2022.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
8 Sundling KE, Antic T, Pambuccian SE. Pathogenesis of Urothelial Carcinoma. The Paris System for Reporting Urinary Cytology 2022. [DOI: 10.1007/978-3-030-88686-8_1] [Reference Citation Analysis]
9 Lopez-Beltran A, Blanca A, Cimadamore A, Gogna R, Montironi R, Cheng L. Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis. Cancers (Basel) 2021;13:5500. [PMID: 34771663 DOI: 10.3390/cancers13215500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]